Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.48 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.48 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.41 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 2/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507884 | 0.98 | — | — | |
| SCHEMBL29404365 | 0.98 | — | — | |
| SCHEMBL31204392 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL6444627 | 0.95 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TSHRCYP1A2 | |
| SCHEMBL8840321 | 0.95 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TSHRCYP1A2 | |
| Bromide SCHEMBL28204005 | 0.81 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3TSHRCYP1A2 | |
| Bromide SCHEMBL18632030 | 0.81 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3TSHRCYP1A2 | |
| SCHEMBL9993603 | 0.80 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TSHRCYP1A2 | |
| SCHEMBL17603147 | 0.79 | — | — | |
| SCHEMBL243460 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663533-B2 | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2920183-B1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| CN-104066732-B | Novel antiviral Pyrrolopyridine derivatives and preparation method thereof | KOREA CHEMICAL RESEARCH INSTITUTE (KR) | 2016-04-13 | — | — | CN | disclosed |
| CN-103153968-B | Triazole derivative and pharmaceutical composition containing same and having analgesic effect | SHIONOGI & CO.,LTD. (JP) | 2016-02-03 | — | — | CN | disclosed |
| CN-103502237-B | Faah inhibitor | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-01-20 | — | — | CN | disclosed |
| CN-105254557-A | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC | 2016-01-20 | — | — | CN | disclosed |
| CN-105218565-A | Spiral shell oxindole compounds and the purposes as therapeutical agent thereof | XENON PHARMACEUTICALS INC | 2016-01-06 | — | — | CN | disclosed |
| CN-105209429-A | Ship1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS INC | 2015-12-30 | — | — | CN | disclosed |
| CN-105175433-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-12-23 | — | — | CN | disclosed |
| CN-1875016-A | Imidazole derivatives | HOFFMANN LA ROCHE (CH) | 2006-12-06 | — | — | CN | disclosed |
| CN-1856470-A | Quinoline potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1723196-A | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2006-01-18 | — | — | CN | disclosed |
| EP-1448196-B1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | EP | disclosed |
| CN-1604897-A | 7-amino-benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-04-06 | — | — | CN | disclosed |
| CN-1596255-A | Heterocyclic compounds with potent chemokine receptor binding | ANORMED INC (CA) | 2005-03-16 | — | — | CN | disclosed |
| CN-1589146-A | Benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-03-02 | — | — | CN | disclosed |
| EP-1448196-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. Hoffmann-La Roche AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-6599901-B1 | Adenosine receptor ligands used in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease | HOFFMAN-LA ROCHE INC. | 2003-07-29 | — | — | US | disclosed |
| WO-2003043634-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | BRD4, BET1, BRD3 | SLC6A2 2501/4885SLC6A4 3666/4885SLC6A3 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.